Moleculin to Seek Accelerated FDA Approval and Plans for Pivotal Phase 2 AML Trial
Following Successful Completion of US Phase 1 TrialHOUSTON, Feb. 5, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors,...
Moleculin Announces Successful Completion of US Phase 1 AML Trial of Annamycin
No evidence of cardiotoxicity; preliminary assessment shows efficacy in 2 out of 6 patients; Company updates interim Phase 1 trial results in EuropeHOUSTON, Feb. 3, 2020 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage...
Moleculin Announces New Data Shows Reversal of Tumor Activity in Animal Models
Annamycin shows unusually high lung uptake and anticancer activity against lung metastases of multiple solid tumorsHOUSTON, Dec. 19, 2019 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad...
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
No evidence of cardiotoxicity to date; 40% of 10 patients dosed at 120 mg/m² demonstrate efficacy; trial progresses in Europe to 210 mg/m²HOUSTON, Dec. 4, 2019 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage...
Moleculin Announces Positive Trial Data with 100% Safe Delivery of p-STAT3 Inhibitor and Efficacy in Majority of Patients
Preliminary results from phase 1 clinical trial of WP1220 for treatment of cutaneous T-cell lymphoma; supports phase 2 studyHOUSTON, Nov. 19, 2019 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a...
Moleculin Announces Beginning of Preclinical Development of New Approach to Pancreatic Cancer
Inhibitor of glycolysis provides opportunity to attack the metabolism of tumorsHOUSTON, Nov. 13, 2019 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting...
Moleculin Announces FDA Approval of IND for its STAT3 Inhibitor in Emory University Clinical Trial
Approval gives green light to study of WP1066 for treatment of pediatric brain cancerHOUSTON, Nov. 12, 2019 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates...
Moleculin Biotech, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2019
HOUSTON, Nov. 12, 2019 -- Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced its financial results for the third...
Moleculin Announces New Data Confirms Anti-tumor Efficacy of Annamycin in Both Human and Murine AML Models
Data Presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics ConferenceHOUSTON, Oct. 29, 2019 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates...
Moleculin Increases Annamycin Production Due to Positive Clinical Trial Activity and Expanded Potential Indications
Expansion of potential indications includes lung-localized tumorsHOUSTON, Oct. 22, 2019 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly...